Literature DB >> 2312505

Opposite effects of monokines (interleukin-1 and tumor necrosis factor) on proliferation and heparin-binding (fibroblast) growth factor binding to human aortic endothelial and smooth muscle cells.

H Sawada1, M Kan, W L McKeehan.   

Abstract

Heparin-binding (fibroblast) growth factors (HBGF) are mitogens for both human aortic endothelial and smooth muscle cells. Under similar conditions, both vascular cells display similar numbers of specific HBGF binding sites with similar apparent affinity for HBGF. The monokines, interleukin-1 and tumor necrosis factor, inhibit endothelial cell growth and stimulate smooth muscle cell growth. The opposite mitogenic effects correlate with reduction and increase in HBGF receptor number displayed by endothelial and smooth muscle cells, respectively. These results suggest that the two monokines may depress endothelial cell regeneration and augment smooth muscle cell hyperplasia by differential modulation of the HBGF receptor in the two vascular cell types.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2312505     DOI: 10.1007/bf02624115

Source DB:  PubMed          Journal:  In Vitro Cell Dev Biol        ISSN: 0883-8364


  18 in total

1.  Heparin-binding (fibroblast) growth factors type one and two genes are co-expressed in proliferating normal human vascular endothelial and smooth muscle cells in culture.

Authors:  P E Mansson; M Malark; H Sawada; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol       Date:  1990-02

2.  Isolation and characterization of different molecular and chromatographic forms of heparin-binding growth factor 1 from bovine brain.

Authors:  W L McKeehan; J W Crabb
Journal:  Anal Biochem       Date:  1987-08-01       Impact factor: 3.365

3.  Tumor necrosis factor type alpha, a potent inhibitor of endothelial cell growth in vitro, is angiogenic in vivo.

Authors:  M Fràter-Schröder; W Risau; R Hallmann; P Gautschi; P Böhlen
Journal:  Proc Natl Acad Sci U S A       Date:  1987-08       Impact factor: 11.205

4.  Human vascular smooth muscle cells both express and respond to heparin-binding growth factor I (endothelial cell growth factor).

Authors:  J A Winkles; R Friesel; W H Burgess; R Howk; T Mehlman; R Weinstein; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

Review 5.  The pathogenesis of atherosclerosis--an update.

Authors:  R Ross
Journal:  N Engl J Med       Date:  1986-02-20       Impact factor: 91.245

Review 6.  Replication of arterial smooth muscle cells in hypertension and atherosclerosis.

Authors:  D Gordon; S M Schwartz
Journal:  Am J Cardiol       Date:  1987-01-23       Impact factor: 2.778

Review 7.  The pathogenesis of atherosclerosis (first of two parts).

Authors:  R Ross; J A Glomset
Journal:  N Engl J Med       Date:  1976-08-12       Impact factor: 91.245

8.  The role of endothelial injury and platelet and macrophage interactions in atherosclerosis.

Authors:  R Ross; A Faggiotto; D Bowen-Pope; E Raines
Journal:  Circulation       Date:  1984-11       Impact factor: 29.690

9.  Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids.

Authors:  P Libby; S J Warner; G B Friedman
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

10.  Inhibition of endothelial cell proliferation by gamma-interferon.

Authors:  R Friesel; A Komoriya; T Maciag
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  11 in total

1.  Heparin-binding (fibroblast) growth factors type one and two genes are co-expressed in proliferating normal human vascular endothelial and smooth muscle cells in culture.

Authors:  P E Mansson; M Malark; H Sawada; M Kan; W L McKeehan
Journal:  In Vitro Cell Dev Biol       Date:  1990-02

Review 2.  Frontiers in mammalian cell culture.

Authors:  W L McKeehan; D Barnes; L Reid; E Stanbridge; H Murakami; G H Sato
Journal:  In Vitro Cell Dev Biol       Date:  1990-01

3.  Effect of recombinant growth factors on human saphenous vein smooth muscle cells.

Authors:  P Dunlop; K Porter; K Varty; P Bell; N London
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.416

4.  TNF-α-mediated proliferation of vascular smooth muscle cells involves Raf-1-mediated inactivation of Rb and transcription of E2F1-regulated genes.

Authors:  Rebecca Davis; Smitha Pillai; Nicholas Lawrence; Said Sebti; Srikumar P Chellappan
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

5.  Mechanical signals activate vascular endothelial growth factor receptor-2 to upregulate endothelial cell proliferation during inflammation.

Authors:  Jie Liu; Sudha Agarwal
Journal:  J Immunol       Date:  2010-06-14       Impact factor: 5.422

6.  Systemic treatment with murine recombinant interleukin-1 beta inhibits the growth and progression of malignant glioma in the rat.

Authors:  C D Rice; R E Merchant
Journal:  J Neurooncol       Date:  1992-05       Impact factor: 4.130

Review 7.  Mechanisms of restenosis.

Authors:  W Casscells; D Engler; J T Willerson
Journal:  Tex Heart Inst J       Date:  1994

8.  Post-transcriptional regulation of interleukin 1 alpha in various strains of young and senescent human umbilical vein endothelial cells.

Authors:  S Garfinkel; S Brown; J H Wessendorf; T Maciag
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

9.  Brain microvascular smooth muscle and endothelial cells produce granulocyte macrophage colony-stimulating factor and support colony formation of granulocyte-macrophage-like cells.

Authors:  M N Hart; Z Fabry; L Love-Homan; J Keiner; K L Sadewasser; S A Moore
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

10.  Smooth muscle cells of the coronary arterial tunica media express tumor necrosis factor-alpha and proliferate during acute rejection of rabbit cardiac allografts.

Authors:  H Tanaka; S J Swanson; G Sukhova; F J Schoen; P Libby
Journal:  Am J Pathol       Date:  1995-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.